|
1
|
Pelle AJ, Loerbroks A, Widdershoven JW and
Denollet J: Heart failure and comorbid diabetes mellitus or chronic
obstructive pulmonary disease: effects on mood in outpatients. Int
J Cardiol. 154:216–217. 2012. View Article : Google Scholar
|
|
2
|
Li B, Zheng Z, Wei Y, et al: Therapeutic
effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc
Diabetol. 10:692011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Asghar O, Al-Sunni A, Khavandi K, et al:
Diabetic cardiomyopathy. Clin Sci (Lond). 116:741–760. 2009.
View Article : Google Scholar
|
|
4
|
Avogaro A, Vigili de Kreutzenberg S, Negut
C, Tiengo A and Scognamiglio R: Diabetic cardiomyopathy: a
metabolic perspective. Am J Cardiol. 93:13A–16A. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee SW, Song KE, Shin DS, et al:
Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9
in patients with type-2 diabetes. Diabetes Res Clin Pract.
69:175–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tucholski J and Johnson GV: Tissue
transglutaminase differentially modulates apoptosis in a
stimuli-dependent manner. J Neurochem. 81:780–791. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barsigian C, Stern AM and Martinez J:
Tissue (type II) transglutaminase covalently incorporates itself,
fibrinogen, or fibronectin into high molecular weight complexes on
the extracellular surface of isolated hepatocytes. Use of
2-[(2-oxopropyl)thio] imidazolium derivatives as cellular
transglutaminase inactivators. J Biol Chem. 266:22501–22509.
1991.PubMed/NCBI
|
|
8
|
Song H, Kim BK, Chang W, et al: Tissue
transglutaminase 2 promotes apoptosis of rat neonatal
cardiomyocytes under oxidative stress. J Recept Signal Transduct
Res. 31:66–74. 2011. View Article : Google Scholar
|
|
9
|
Lauzier A, Charbonneau M, Paquette M,
Harper K and Dubois CM: Transglutaminase 2 cross-linking activity
is linked to invadopodia formation and cartilage breakdown in
arthritis. Arthritis Res Ther. 14:R1592012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Z, Wang S, Zhou S, et al:
Sulforaphane prevents the development of cardiomyopathy in type 2
diabetic mice probably by reversing oxidative stress-induced
inhibition of LKB1/AMPK pathway. J Mol Cell Cardiol. Sep
28–2014.(Epub ahead of print). View Article : Google Scholar
|
|
11
|
Kappel VD, Cazarolli LH, Pereira DF, et
al: Involvement of GLUT-4 in the stimulatory effect of rutin on
glucose uptake in rat soleus muscle. J Pharm Pharmacol.
65:1179–1186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boudina S and Abel ED: Diabetic
cardiomyopathy revisited. Circulation. 115:3213–3223. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mäki M: Tissue transglutaminase as the
autoantigen of coeliac disease. Gut. 41:565–566. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liao CW, Fan CK, Kao TC, et al: Brain
injury-associated biomarkers of TGF-beta1, S100B, GFAP, NF-L, tTG,
AbetaPP, and tau were concomitantly enhanced and the UPS was
impaired during acute brain injury caused by Toxocara canis in
mice. BMC Infect Dis. 8:842008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petrak J, Pospisilova J, Sedinova M, et
al: Proteomic and transcriptomic analysis of heart failure due to
volume overload in a rat aorto-caval fistula model provides support
for new potential therapeutic targets - monoamine oxidase A and
transglutaminase 2. Proteome Sci. 9:692011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mirza A, Liu SL, Frizell E, et al: A role
for tissue transglutaminase in hepatic injury and fibrogenesis, and
its regulation by NF-kappaB. Am J Physiol. 272:G281–G288.
1997.PubMed/NCBI
|
|
17
|
Hao HH, Shao ZM, Tang DQ, et al:
Preventive effects of rutin on the development of experimental
diabetic nephropathy in rats. Life Sci. 91:959–967. 2012.
View Article : Google Scholar : PubMed/NCBI
|
